Meet Young Hee Ko M.S., M.S., Ph.D. 

I have been very fortunate in my scientific career. My previous mentors/professors allowed me to stand on their shoulders and see much further than I would have alone. They trained me in the fields of nutrition, metabolism, chemistry, biochemistry, biophysics, biology, microbiology, physiology, and animal care medicine. Additionally, I gained hands-on experience in human medicine by collaborating with research scientists, physicians, healthcare providers, radiologists, patients, and patient family members. My ongoing goal is to better understand human biology and biochemistry, and to identify key and subtle differences between health and disease. My most important goal is to discover and develop new therapies targeting major diseases that affect humans and animals around the world.

My immediate plan is to develop 3BP anticancer technology for global commercialization to help as many cancer patients as possible. In 2000, I discovered that the small molecule 3-bromopyruvate (3BP) is a highly potent and effective anticancer agent with preferential selectivity for cancer cells. 3BP works by targeting the most common property of cancer cells - their markedly elevated capacity to metabolize glucose and glutamine. It enters cancer cells quickly via mono-carboxylate transporters (MCTs) and immediately targets the mitochondria. It does all of this while leaving most normal cells unharmed.

I founded a start-up company called KoDiscovery to further develop 3BP as an anticancer therapy. I hope to help patients who have run out of treatment options, and those who wish to be treated with 3BP as the first therapy. Ultimately, I will work on a myriad of additional research projects associated with neurological diseases, injuries/wounds, infections, inflammation, and other health conditions, in order to help the millions affected by these devastating conditions. 

With gratitude,
Young Ko

January 2, 2019 - NEWS Update

August 2018 Update - Study Summary! 

                    March, 2018

KoDiscovery, LLC in partnership with The University of Maryland announces a New Preclinical Study

Dear Friends,

I am very happy to let you know that I am now working with the University of Maryland on an important preclinical cancer study. It seems that, as always, working through the necessary steps to achieve any worthwhile goal takes so much longer than we want them to take. Even so, I am hopeful that we are now making progress to receive the necessary preclinical data which will lead to the next important step of human clinical trials for 3BP as an effective anticancer therapy.

All of the critical approvals have been received through the University of Maryland, our animals have been purchased for

the study, and we are in process of developing the tumor growth necessary to soon begin treatments with 3BP. A significant part of this study will focus on the potential effectiveness of radiation as a beneficial signaler to enhance the effectiveness of 3BP as an anticancer therapy. As our study moves forward, I will try to provide some brief updates regarding our progress. 


I would also very much like to express my deep gratitude to all who have supported this collaboration with the University of Maryland. Because of your faith in me and your compassionate hearts, this important preclinical study is now a reality. It is my hope and dream that we will soon be able to move forward from this study to human clinical trials and then to our final goal of FDA approval to provide 3BP to all of those in need. 

Thank you again for your interest and support.


With gratitude,